The association between azacitidine (AZA) and valproic acid (VPA) has shown high response rates in high-risk myelodysplastic syndromes (MDS) cases with unfavorable prognosis. However, little is known about the molecular mechanisms underlying this therapy, and molecular markers useful to monitor the disease and the effect of the treatment are needed. Phosphoinositide-phospholipase C (PI-PLC) b1 is involved in both genetic and epigenetic mechanisms of MDS progression to acute myeloid leukemia. Indeed, AZA as a single agent was able to induce PI-PLCb1 expression, therefore providing a promising new tool in the evaluation of response to demethylating therapies. In this study, we assessed the efficacy of the combination of AZA and VPA on inducing PI-PLCb1 expression in high-risk MDS patients. Furthermore, we observed an increase in Cyclin D3 expression, a downstream target of PI-PLCb1 signaling, therefore suggesting a potential combined activity of AZA and VPA in high-risk MDS in activating PI-PLCb1 signaling, thus affecting cell proliferation and differentiation. Taken together, our findings might open up new lines of investigations aiming at evaluating the role of the activation of PI-PLCb1 signaling in the epigenetic therapy, which may also lead to the identification of innovative targets for the epigenetic therapy of high-risk MDS.
Introduction
Among epigenetic processes, promoter DNA hypermethylation is now considered a common hallmark of cancer and, in contrast to deletions or mutations of tumour suppressor genes, the gene silencing induced by this phenomenon can be reversed. 1, 2 Interestingly, the effect of the epigenetic therapy is not only based on anti-proliferative activity but also on inducing cell differentiation, as demethylating agents have been demonstrated to induce hematopoietic differentiation. [3] [4] [5] [6] That is why new approaches based on epigenetic targeting are currently used in the hematological malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) , that frequently show promoter hypermethylation of critical genes involved in cell proliferation and differentiation. 7 Indeed, azacitidine (AZA) is a cytosine-nucleoside analog acting as a DNA methyltransferase inhibitor, which is currently administered to high-risk MDS patients and has proven effectiveness in prolonging the overall survival and delaying AML evolution, especially in patients with more advanced disease. 8, 9 The biochemical modification of chromatin-associated histone proteins, such as acetylation of histone H3 or H4, is another epigenetic regulatory mechanism of gene expression involved in leukemogenesis. 10 This process is controlled by both histone acetyl-transferases and deacetylases, and can be prevented by histone deacetylase (HDAC) inhibitors, which can modulate chromatin structure and target other several nonhistone substrates through histone acetylation, thus determining changes in gene transcription, and also inducing other biological effects, such as apoptosis, differentiation, inhibition of angiogenesis or modulation of immune responses. 11, 12 Strategies of combining different drugs aim at increasing the efficacy of the single agents, therefore improving response rates, prolonging response duration, and decreasing the toxicities associated with the treatment. 13 That is why several combination therapies are beginning to be tested, either as chemosensitizing agents in association with standard chemotherapy or combination of epigenetic drugs, aiming at reverting methylation of clonal cells. 14, 15 Combination of the DNA methyltransferase inhibitor AZA and the HDAC inhibitor valproic acid (VPA) in patients having MDS and belonging to the International Prognostic Scoring System risk group intermediate-2/high is active and associated with a high response rate in these MDS patients, usually with unfavorable prognosis. 16, 17 However, at present, there are no valuable parameters, either diseaseassociated or patient-associated, predictive of response to DNA methyltransferase inhibitors or to the combination of DNA methyltransferase inhibitors and HDAC inhibitors, which could be also useful to monitor the efficacy of the treatment, even though current studies focusing on hypomethylation and gene reexpression in MDS are trying to asses the optimal epigenetic drug targets, and the molecular mechanisms underlying clinical response to demethylating therapy. 18, 19 Lipid signaling in disease is an important field of investigation, and phosphoinositides have been demonstrated to be involved in leukemogenesis. 20, 21 Namely, phosphoinositide-phospholipase C (PI-PLC) b1 is a key enzyme acting on cell proliferation and differentiation, mainly targeting Cyclin D3, 22, 23 which is involved in G1 progression, and, more importantly, has been demonstrated to be highly expressed in the early stages of the hematopoietic differentiation. 24, 25 PI-PLCb1 has also been demonstrated to have a role both in the genetic 26 and in the epigenetic mechanisms of MDS progression to AML. 27, 28 As for this latter, recent studies showed not only that PI-PLCb1 promoter gene is hypermethylated in high-risk MDS patients but also that it can be a specific target for AZA. Indeed, the amount of PI-PLCb1 messenger RNA could predict the clinical response to AZA, therefore indicating a promising new tool in the evaluation of response to demethylating therapies. 28 Moreover, it has been demonstrated that AZA efficacy on increasing PI-PLCb1 gene expression can be accompanied by an inverse correlation to the degree of Akt activation. 27 In this study, we further investigated the role of PI-PLCb1 signaling in epigenetic processes, focusing on the effect of the combination of AZA and VPA on signal transduction molecules. Firstly, we examined whether the combination of AZA and VPA affects PI-PLCb1 methylation and expression in MDS cells, then we assessed the effect of these drugs on PI-PLCb1 downstream target Cyclin D3, and finally we investigated the connection between PI-PLCb1 promoter methylation and gene expression with the clinical response to the combination of AZA and VPA, comparing the results with the effect obtained by AZA alone.
Materials and methods

Patient characteristics
Bone Marrow and Peripheral Blood samples came from 20 MDS patients and 10 healthy normal volunteers who had given informed consent according to the Declaration of Helsinki. All the samples came from the Department of Hematology and Medical Oncology 'L. e A. Seràgnoli' of the Policlinico S. Orsola-Malpighi, Bologna, Italy. Patients were observed between 2002 and 2009 and the median follow-up was 32 months (range 19-67 months) for patients treated with AZA alone, 39.5 months (range 27-62 months) for patients receiving the combination of AZA and VPA and 11 months (range 3-42 months) for patients treated with best supportive care only. In all the subjects participating in this study MDS diagnosis was defined according to both French-American-British 29 and World Health Organization classifications, 30, 31 whereas the International Prognostic Scoring System was used to divide the patients into intermediate 2-and high-risk group. 32 However, throughout the text, all of the MDS patients are defined as high-risk MDS. As initially French-American-British classification was used, 29 in the group of patients receiving best supportive care only, one patient with refractory anemia with excess of blasts in transformation was included, subsequently diagnosed as AML, following World Health Organization classification. 30, 31 Patient treatments and evaluation of response Eight of the MDS patients underwent subcutaneous AZA treatment (75 mg/m 2 per day for 7 days in each 28-day cycle), whereas six patients received best supportive care only. As for the combination of AZA and VPA, which was given to six patients, AZA was administered subcutaneously at a standard dose of 75 mg/m 2 daily, for 7 days in each 28-day cycles for eight cycles, whereas VPA was given orally at a dose ranging from 600 to 1500 mg daily, every 4 weeks, in order to reach a VPA final plasma concentration 450 mg/ml. In case of failure after four cycles of the combination of AZA and VPA, Retinoic Acid (ATRA) was administered at 30 mg/m 2 orally daily, on days 8-27 for four cycles, but, as soon as they received ATRA, these patients were excluded from further analyses, as this study focused only on AZA and VPA effect. Treatment was continued in responder patients until disease progression, toxicity or death, but our molecular analyses assessed the effect of AZA, alone or in combination with VPA, for a maximum of eight cycles.
Hematologic response or treatment failure were defined according to the revised International Working Group response criteria for MDS. 33 In particular, hematologic response was defined as complete remission, partial remission or hematologic improvement. Other outcomes included stable disease, failure, relapse, disease progression or disease transformation into AML.
Isolation of mononuclear cells (MNCs) and CD34 þ cells from bone marrow or peripheral blood samples For in vitro experiments, MNCs were isolated by Ficoll-Paque (GE Healthcare, Waukesha, WI, USA) density-gradient centrifugation, according to the manufacturer's instructions. All analyses were performed on samples from patients at baseline, and subsequently before each cycle of AZA or the combination of AZA and VPA. CD34 þ cells were obtained from total MNCs after immunomagnetic separation using the CD34 Micro Beads kit (Miltenyi Biotec, Bergisch Gladbach, Germany) following the manufacturer's protocol.
Fluorescence in situ hybridization (FISH) analysis
Cytogenetic investigations were performed on phytohemagglutinstimulated bone marrow cells at the time of diagnosis to assess the cytogenetic status of PI-PLCb1 gene, as described elsewhere. 26 
Antibodies and reagents
The following antibodies and reagents were purchased from commercial sources. For in vitro experiments on cell lines, AZA (#A2385) and VPA (#P4543) were purchased from Sigma-Aldrich (St Louis, MO, USA). PI-PLCb1 mouse-primary antibody was from Millipore/Upstate (Billerica, MA, USA) (#05-164), whereas mouse Cyclin D3 (#2936), rabbit Akt (#9272), rabbit p-Akt Ser473 (#4058) and rabbit b-actin (#4967) primary antibodies, as well as horseradish peroxidase-conjugated anti-rabbit IgG (#7074), horseradish peroxidase-conjugated antimouse IgG (#7076) and the Phototope-horseradish peroxidase western blot detection system (#7071) were from Cell Signaling Technology (Beverly, MA, USA). For immunocytochemical analyses, the secondary antibodies were fluorescein isothiocyanate-conjugated F(ab) 2 fragment of goat anti-rabbit IgG (#F1262, Sigma-Aldrich) and fluorescein isothiocyanate-conjugated F(ab) 2 fragment of sheep anti-mouse IgG (#2883, Sigma-Aldrich).
Tissue cell cultures
HL60 acute promyelocytic leukemia cell line and U937 monocytic cell line were cultured at 37 1C with 5% CO 2 in RPMI 1640 medium (Cambrex Bio Science, Verviers, Belgium), supplemented with 10% heat-inactivated fetal bovine serum and streptomycin/penicillin, at an optimal cell density of 0.3-0.8 Â 10 6 cells/ml. These two cell lines were used, respectively, as a positive and negative control for PI-PLCb1 methylation, as previously described. 28 In all in vitro experiments, AZA was administered at 5 mM for 24 h, whereas cells were exposed to VPA for 24 h at a final concentration of 0.3 mM.
Nucleic acids extraction
Genomic DNA and total RNA were isolated from cell lines, CD34 þ and total MNCs from MDS patients and healthy subjects by using the QIAamp DNA Blood Mini Kit and the RNeasy Mini Kit (both from Qiagen Ltd, Valencia, CA, USA) according to the manufacturer's protocol, then RNA was retrotranscribed as described elsewhere. 34 Bisulfite DNA modification and real-time methylationspecific PCR DNA was bisulfite-converted by the MOD50 kit (Sigma-Aldrich) according to the manufacturer's instructions. The degree of PI-PLCb1 promoter methylation was quantified by a standard SYBR-Green Real-Time methylation-specific PCR method using the glyceraldehyde-3-phosphate-dehydrogenase as a reference gene, as previously described. 28 
PI-PLCb1 gene expression analysis
The expression of PI-PLCb1a (Hs01008373_m1, Applied Biosystems, Foster City, CA, USA) and PI-PLCb1b (Hs01001939_m1, Applied Biosystems) splicing variants, as well as Cyclin D3 messenger RNA (Hs00236949_m1, Applied Biosystems), were quantified by a TaqMan Real-Time PCR method, with the glyceraldehyde-3-phosphate-dehydrogenase gene (Hs99999905_m1, Applied Biosystems) as the internal reference, as described elsewhere. 34 Data were statistically analyzed by the GraphPad Prism software (v.3.0, La Jolla, CA, USA), using healthy subjects as the calibrator.
Immunocytochemistry analysis
HL60 cells, U937 cells and freshly isolated MNCs were collected by centrifugation at a density of 0.3 Â 10 6 cells/ml and immunostaining analysis was performed as previously described. 35 For quantification of immunoreactivity, at least 50-100 cells per slide were counted.
Western blot
Equal number of cells (5 Â 10 6 ) from HL60 and U937 cells were collected by centrifugation and resuspended in M-PER Extraction Reagent (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer's instructions. The protein content was quantified using a BCA protein assay (Pierce Biotechnology) and equal protein amounts (75 mg) were separated by SDS-PAGE, as previously described. 36 
Results
Patient characteristics
Bone Marrow or Peripheral Blood MNCs from 20 patients affected by MDS (eight treated with AZA alone, six with the combination of AZA and VPA, and six with best supportive care only) were examined. In our case series, median age was 65.5 years (range 62-84 years) for patients treated with AZA alone, 76.5 years (range 50-80 years) for patients receiving the combination of AZA and VPA, and 73 years (range 50-78 years) for patients treated with best supportive care only. For all cases, MDS was diagnosed following both French-American-British and World Health Organization classifications, [29] [30] [31] whereas, according to the International Prognostic Scoring System, 32 patients were divided into two risk subgroups: intermediate-2 risk (n ¼ 16) and high-risk (n ¼ 4). However, throughout the text, all of the MDS patients are defined as high-risk MDS. Patient demographics and disease characteristics are summarized in Table 1 , where also the cytogenetic status of PI-PLCb1 is reported.
Study group and clinical response
Between February 2002 and December 2009, eight high-risk MDS patients were treated with AZA alone, receiving a median number of 14.5 (range 7-54) courses. According to the revised International Working Group criteria, 33 five of these patients (62.5%) showed a favorable response to treatment: complete remission (one patient), partial remission (one patient) and hematologic improvement (three patients). The remaining three patients did not respond to AZA. As for the combination of AZA and VPA, six patients were treated for a median number of 9.5 cycles (range 8-18) and three of them (50%) showed hematologic improvement, whereas the remaining three patients (50%) did not respond, and maintained a stable disease. (Table 1) . The patient was added ATRA, but as soon as it received ATRA therapy it was excluded from our molecular analyses.
AZA and VPA induce a PI-PLCb1 DNA hypomethylation and an increase in gene and protein expression in hematopoietic cell lines HL60 and U937 cells were incubated for 24 h with AZA 5 mM and VPA 0.3 mM, alone or in combination. The effect of AZA as hypomethylating agent was quantified by Real-Time methylation-specific PCR, whereas VPA effect as HDAC inhibitor was assessed by chromatin immunoprecipitation experiments on acetyl-histone H3 (data not shown). The treatment with AZA, alone or in combination with VPA, but not VPA alone, induced a specific hypomethylation of PI-PLCb1 promoter and an induction of both PI-PLCb1 gene and protein expression in HL60, but not in U937 cells, which was higher for cells treated with both AZA and VPA (Figure 1) . Moreover, as previously described, 28 the correlation between PI-PLCb1b splicing variant and the degree of PI-PLCb1 demethylation was stronger than the one with PI-PLCb1a (data not shown), that is why all subsequent analyses focused only on the nuclear splicing variant PI-PLCb1b, subsequently defined as PI-PLCb1.
The combination of AZA and VPA induces Cyclin D3 expression in hematopoietic cell lines
Given that PI-PLCb1 targets Cyclin D3, 22, 23 the effects of the combination of AZA and VPA on Cyclin D3 expression were also investigated. As Figure 2 shows, gene expression analyses, western blot experiments and immunocytochemical investigations confirmed the specific induction of Cyclin D3 expression in HL60 cells treated with AZA, which was enhanced in cells receiving the combination of AZA and VPA, but not in HL60 cells exposed to VPA alone, nor in U937 cell line (Figure 2 ).
VPA enhances the demethylating effect of AZA in high-risk MDS patients
Genomic DNA from healthy subjects and MDS samples was extracted and bisulfite-modified, so as to analyze the status of promoter methylation before and during the therapy. First of all, we confirmed that in CD34 þ cells the degree of PI-PLCb1 methylation was not significantly different from the results obtained by the analysis of MNCs (data not shown), as also previously stated. 28 Then, we quantified the amount of PI-PLCb1 promoter methylation in patients treated with AZA alone, the combination of AZA and VPA, and only best supportive care. As compared with the pre-treatment amount, responder patients to AZA alone or the combination of AZA and VPA demonstrated a marked decrease in PI-PLCb1 promoter methylation ( Figure 3a , Table 1 ). The differences between PI-PLCb1 promoter methylation and baseline, calculated as a percentage rate on the pre-treatment level of the same patient, were statistically significant (Student's t-test, Po0.05 vs baseline, 95% confidence interval (CI) À46.87 to þ 14.69 in patients treated with AZA alone; Student's t-test, Po0.05 vs baseline, 95% CI, À48.02 to þ 18.98 in patients receiving AZA and VPA). As for patients treated with best supportive care only, they did not show any significant change in PI-PLCb1 promoter methylation (Student's t-test, P40.1, 95% CI, À4.15 to þ 2.79). For all patients analyzed, the differences between baseline and the median levels of PI-PLCb1 promoter methylation during followup are reported in Table 1 : positive values indicate an increase, whereas negative values indicate a reduction. Interestingly, the comparison between the treatment with AZA alone and the combination of AZA and VPA showed that this latter is more effective in inducing hypomethylation of PI-PLCb1 promoter (Student's t-test, Po0.5, 95% CI, À15.58 to þ 18.12).
VPA increases the effect of AZA on PI-PLCb1 gene and protein expression in high-risk MDS patients
To determine whether PI-PLCb1 gene expression could be induced in vivo by AZA therapy, we analyzed the MDS samples at baseline and before the beginning of each single course of AZA alone, or the combination of AZA and VPA (Figure 3a) . The differences between PI-PLCb1 gene expression during the therapy and baseline, calculated as a percentage rate on the pre-treatment level of the same patient, were statistically significant for every group of patients (Student's t-test, Po0.05 vs baseline, 95% CI, À7.39 to þ 47.35 in patients treated with AZA alone; Student's t-test, Po0.05 vs baseline, 95% CI, À12.51 to þ 47.55 in patients receiving AZA and VPA). In contrast, patients treated only with best supportive care did not show any significant alteration in PI-PLCb1 messenger RNA (Student's t-test, Po0.05 vs baseline, 95% CI, À0.32 to þ 4.04). Overall, patients treated with AZA or the combination of AZA and VPA who responded to the therapy showed a significant increment of PI-PLCb1 gene expression, with a statistically significant difference between pre-and post-treatment. As for PI-PLCb1 protein expression, as in most cases the number of MDS cells available for each sample was limited, we performed only immunocytochemical investigations. The analyses, carried out on samples before and during the therapies, confirmed the results obtained by real-time PCR experiments, that is, responder patients to AZA alone showed an increase in PI-PLCb1, which was more remarkable in patients exposed to the combination of AZA and VPA, whereas it slightly lowered in non responders (Figure 3b) .
VPA increases the effect of AZA on Cyclin D3 gene and protein expression in high-risk MDS patients
To assess whether also in vivo PI-PLCb1 reactivation could be associated with an increase in Cyclin D3 expression, we analyzed the MDS samples at baseline and before the beginning of each single course of AZA, alone or in combination with VPA ( Figure 4a ). All in all, patients treated with AZA alone who responded to the therapy showed a considerable increment of Cyclin D3 gene and protein expression, which was greater for patients exposed to both AZA and VPA, with a statistically significant difference between pre-and post-treatment. In contrast, non responders did not show any significant alteration in Cyclin D3 levels (Figure 4a ). Given that in most cases the number of MDS cells available for each sample was limited, we evaluated Cyclin D3 protein expression only by immunocytochemical investigations. The analyses were performed on samples before and during the treatments, and confirmed the gene expression analyses. In responder patients, AZA alone induced an increase in Cyclin D3 protein levels, which was more evident in patients treated with AZA and VPA, whereas the amount of Cyclin D3 was almost constant in non responders (Figure 4b ).
AZA and VPA combination treatment results in downregulation of p-Akt
As an inverse correlation between PI-PLCb1 and p-Akt has been reported, 27 we investigated the effect of AZA, alone or in combination with VPA, on the activation of Akt. The levels of Akt and activated (phosphorylated)-Akt in HL60 and U937 cells following AZA and the combination of AZA and VPA were quantified by both western blotting and immunostaining (Figures 5a and b) , whereas the degree of Akt activation on MDS samples from patients treated with AZA or the combination of AZA and VPA was assessed by immunocytochemistry only, because of the limited amount of material ( Figure 5c ). As Figure 5 shows, AZA alone induced a specific downregulation of p-Akt in HL60 cells, which was enhanced after treatment with AZA and VPA, whereas VPA alone slightly activated and phosphorylated Akt. As for MDS patients, AZA alone or in combination with VPA induced a slight decrease in p-Akt levels in responders, whereas non responders had almost constant levels of p-Akt.
Discussion
Epigenetic targeting has recently gained great interest as a new and effective treatment option for patients with MDS. AZA is a DNA methyltransferase inhibitor that has been proven to be effective in high-risk MDS, because it can induce hematologic responses in 50-60% of cases, delay the AML evolution, and prolong the overall survival. 8, 9, 37, 38 On the other hand, the clinical activity of HDAC inhibitors has also demonstrated a therapeutic potential as monotherapy, but above all in combination with a large number of conventional chemotherapeutic drugs, having a synergistic effect in enhancing their anticancer activity. 39, 40 That is why several combination approaches based on HDAC inhibition and other novel drugs are being tested. Currently, the combination of DNA methyltransferase inhibitors, such as AZA, with HDAC inhibitors, like VPA, has been recognized as clinically useful and associated with a high response rate in patients with MDS at higher risk of AML evolution and unfavorable prognosis. 16, 17 However, the biological role of these combination therapies remains to be defined, as the extent to which clinical activity and response depend on epigenetic modulations, as well as the cellular targets or the pathways involved, are still not fully understood. 18 PI-PLCb1 is a well-known enzyme involved in cell proliferation and differentiation. Because of the complexity and extensive crosstalk between PI-PLCb1 and other critical pathways, the comprehension of the role of PI-PLCb1 signaling may provide new insights in the MDS pathogenesis and offer new molecular targets for innovative MDS therapeutic strategies.
Recently, we showed that PI-PLCb1 is involved in the MDS progression to AML, as the monoallelic deletion of PI-PLCb1 gene could be a potential marker for identifying MDS at higher risk of evolution into AML. 26 Interestingly, also in this study the presence of the monoallelic deletion of PI-PLCb1 gene seems to be a prognostic marker for AML evolution, even in the presence of early hypomethylation induced by the therapy.
In our previous work we documented the effect of AZA as a single agent on inducing PI-PLCb1 expression. 28 Here, we demonstrated the efficacy of the combination of AZA and VPA on increasing PI-PLCb1 expression in HL60 cell line and in highrisk MDS patients, which was more effective than AZA alone. Indeed, a comparison between AZA alone and the combination of AZA and VPA documented that the latter was significantly more powerful in HL60 cells, as well as in high-risk MDS cases, on inducing PI-PLCb1 promoter demethylation and reactivation of both gene and protein expression. Moreover, the data obtained from the analysis of U937 cells, that represent our negative control for PI-PLCb1 methylation and are effectively not affected by these concentrations of AZA and VPA, demonstrated that the combination of these drugs specifically target PI-PLCb1 promoter when hypermethylated, as it is in HL60 cells or in several high-risk MDS patients. Remarkably, the combination of AZA and VPA induced a higher demethylation of PI-PLCb1 promoter, as compared with the effect of AZA alone, thus confirming that AZA in combination with HDAC inhibitors, such as VPA, might offer better efficacy by modulating the methylation and acetylation states of silenced genes. 19 Furthermore, our results showed that the treatment with AZA and VPA results in an increase in Cyclin D3 expression. Cyclin D3 is a downstream target of PI-PLCb1 signaling 22, 23 and has a unique function in early hematopoietic differentiation. Indeed, the data presented here prove that AZA alone, but above all the combination of AZA and VPA, can increase the levels of Cyclin D3, thus hinting at an activation of PI-PLCb1 signaling in HL60 cells exposed to demethylating agents. Interestingly, our findings confirmed this activation also in high-risk MDS patients. In fact, MDS cells displaying an increment of PI-PLCb1 expression after exposition to AZA and VPA also showed a concomitant increase in Cyclin D3 expression, as both messenger RNA and protein levels augmented during the therapy. Again, the combination of AZA and VPA seemed to be more effective than AZA alone in inducing Cyclin D3 expression. This finding, along with the fact that not only AZA has been linked to the induction of hematopoietic differentiation 41, 42 but also VPA can induce in vitro differentiation of hematopoietic cell lines and primary AML blasts, 43, 44 lead us to hypothesize that our observations about the effect of AZA, alone or in combination with VPA, could be linked to a role for PI-PLCb1 and Cyclin D3 activation in hematopoietic differentiation, and could therefore be useful for a better comprehension of the molecular mechanisms underlying the epigenetic therapy.
In addition, our results show that the induction of PI-PLCb1 signaling could be associated with a deregulation of Akt activation, thus leading to a better comprehension of the mechanisms leading to AML progression in high-risk MDS. In fact, Akt is a key player of survival pathways whose deregulation has been demonstrated to be implicated in leukemogenesis. 45 Recent studies showed that not only is Akt specifically phosphorylated in MDS patients at higher risk of evolution into AML but also mTOR and its downstream targets are activated, 35 therefore inducing blast cell survival and proliferation. Moreover, it was recently hypothesized an inverse correlation between PI-PLCb1 expression and Akt activation after AZA treatment, 27 therefore hinting at a good prognosis in case of activation of PI-PLCb1 and inhibition of Akt. This hypothesis, along with the fact that AZA alone has been showed to induce PI-PLCb1 expression, lead us to investigate whether even the combination of AZA and VPA could affect PI3K/Akt pathway. Our results suggest a potential increased activity of combination therapy based on AZA and VPA in high-risk MDS in inhibiting Akt activation, as AZA and VPA together caused a higher dephosphorylation of p-Akt in high-risk MDS cases responding to the therapy, as compared with the effect of AZA alone, whereas non responders did not show any significant Akt inhibition.
Taken together, our findings strongly suggest that the effect of AZA alone can be improved by VPA, and that the combination of the two drugs could indeed be a valuable therapeutic strategy for high-risk MDS patients, resulting in an enhanced demethylation and increased expression of PI-PLCb1, therefore affecting cell proliferation and differentiation. Indeed, our data confirm the involvement of PI-PLCb1 signaling in the epigenetic alterations associated with MDS, and may be relevant for better understanding the molecular effects of demethylating agents and of combination therapy based on these drugs in high-risk MDS.
